Materials Map

Discover the materials research landscape. Find experts, partners, networks.

  • About
  • Privacy Policy
  • Legal Notice
  • Contact

The Materials Map is an open tool for improving networking and interdisciplinary exchange within materials research. It enables cross-database search for cooperation and network partners and discovering of the research landscape.

The dashboard provides detailed information about the selected scientist, e.g. publications. The dashboard can be filtered and shows the relationship to co-authors in different diagrams. In addition, a link is provided to find contact information.

×

Materials Map under construction

The Materials Map is still under development. In its current state, it is only based on one single data source and, thus, incomplete and contains duplicates. We are working on incorporating new open data sources like ORCID to improve the quality and the timeliness of our data. We will update Materials Map as soon as possible and kindly ask for your patience.

To Graph

1.080 Topics available

To Map

977 Locations available

693.932 PEOPLE
693.932 People People

693.932 People

Show results for 693.932 people that are selected by your search filters.

←

Page 1 of 27758

→
←

Page 1 of 0

→
PeopleLocationsStatistics
Naji, M.
  • 2
  • 13
  • 3
  • 2025
Motta, Antonella
  • 8
  • 52
  • 159
  • 2025
Aletan, Dirar
  • 1
  • 1
  • 0
  • 2025
Mohamed, Tarek
  • 1
  • 7
  • 2
  • 2025
Ertürk, Emre
  • 2
  • 3
  • 0
  • 2025
Taccardi, Nicola
  • 9
  • 81
  • 75
  • 2025
Kononenko, Denys
  • 1
  • 8
  • 2
  • 2025
Petrov, R. H.Madrid
  • 46
  • 125
  • 1k
  • 2025
Alshaaer, MazenBrussels
  • 17
  • 31
  • 172
  • 2025
Bih, L.
  • 15
  • 44
  • 145
  • 2025
Casati, R.
  • 31
  • 86
  • 661
  • 2025
Muller, Hermance
  • 1
  • 11
  • 0
  • 2025
Kočí, JanPrague
  • 28
  • 34
  • 209
  • 2025
Šuljagić, Marija
  • 10
  • 33
  • 43
  • 2025
Kalteremidou, Kalliopi-ArtemiBrussels
  • 14
  • 22
  • 158
  • 2025
Azam, Siraj
  • 1
  • 3
  • 2
  • 2025
Ospanova, Alyiya
  • 1
  • 6
  • 0
  • 2025
Blanpain, Bart
  • 568
  • 653
  • 13k
  • 2025
Ali, M. A.
  • 7
  • 75
  • 187
  • 2025
Popa, V.
  • 5
  • 12
  • 45
  • 2025
Rančić, M.
  • 2
  • 13
  • 0
  • 2025
Ollier, Nadège
  • 28
  • 75
  • 239
  • 2025
Azevedo, Nuno Monteiro
  • 4
  • 8
  • 25
  • 2025
Landes, Michael
  • 1
  • 9
  • 2
  • 2025
Rignanese, Gian-Marco
  • 15
  • 98
  • 805
  • 2025

Smith, Rebecca

  • Google
  • 6
  • 79
  • 9

Royal Devon & Exeter NHS Foundation Trust

in Cooperation with on an Cooperation-Score of 37%

Topics

Publications (6/6 displayed)

  • 2024P202 Streamlining primary and secondary care pathways reduces the time-to-specialist IBD care: the emergence of FIT and the relative decline of calprotectin testing in primary carecitations
  • 2024OP11 Exploring the potential clinical utility of NUDT15 pharmacogenetic testing in clinical practice: a ‘focused reverse phenotyping’ study in the UK IBD Bioresourcecitations
  • 2024P234 Online direct-to-public calprotectin testing in the UK: what is out there in 2023?citations
  • 2023Evaluating the association of biallelic OGDHL variants with significant phenotypic heterogeneity7citations
  • 2022Metal–ligand Lability and Ligand Mobility Enables Framework Transformation via Ligand Release in a Family of Crystalline 2D Coordination Polymers2citations
  • 2018'Designing' biomass lignins for the biorefinerycitations

Places of action

Chart of shared publication
Cairnes, V.
1 / 1 shared
Ahmad, T.
3 / 11 shared
Goodhand, J.
2 / 2 shared
Bishara, M.
3 / 3 shared
Chee, D.
1 / 1 shared
Djouider, Y.
1 / 1 shared
Kennedy, N.
2 / 3 shared
Roberts, C.
3 / 4 shared
Parkes, M.
1 / 1 shared
Sazonovs, A.
1 / 1 shared
Neil, C.
1 / 1 shared
Bewshea, C.
1 / 1 shared
Warden, S.
1 / 1 shared
Pele, L.
1 / 1 shared
Cocking, L.
1 / 1 shared
Lin, S.
1 / 4 shared
Goodhand, J. R.
1 / 1 shared
Kennedy, N. A.
1 / 1 shared
Nice, R.
1 / 1 shared
Singh, Daljit C. N. G.
1 / 1 shared
Romer, Catherine
1 / 1 shared
Rao, Abhishek B.
1 / 1 shared
Brammer, Lee
1 / 5 shared
Adams, Harry
1 / 1 shared
Wright, James
1 / 1 shared
Boerjan, W.
1 / 1 shared
Luterbacher, Jeremy
1 / 2 shared
Mansfield, S. D.
1 / 1 shared
Motagamwala, Ali Hussain
1 / 1 shared
Dumesic, James
1 / 1 shared
Shuai, Li
1 / 1 shared
Gonzales-Vigil, E.
1 / 1 shared
Zhou, Shengfei
1 / 1 shared
Mottiar, Y.
1 / 1 shared
Dixon, Richard
1 / 1 shared
Rencoret, Jorge
1 / 3 shared
Río Andrade, José Carlos Del
1 / 6 shared
Vanholme, R.
1 / 1 shared
Kim, Hoon
1 / 3 shared
Lan, Wu
1 / 1 shared
Runge, Troy
1 / 1 shared
Ralph, John
1 / 4 shared
Li, Yanding
1 / 1 shared
Karlen, S. D.
1 / 1 shared
Chen, Fang
1 / 1 shared
Chart of publication period
2024
2023
2022
2018

Co-Authors (by relevance)

  • Cairnes, V.
  • Ahmad, T.
  • Goodhand, J.
  • Bishara, M.
  • Chee, D.
  • Djouider, Y.
  • Kennedy, N.
  • Roberts, C.
  • Parkes, M.
  • Sazonovs, A.
  • Neil, C.
  • Bewshea, C.
  • Warden, S.
  • Pele, L.
  • Cocking, L.
  • Lin, S.
  • Goodhand, J. R.
  • Kennedy, N. A.
  • Nice, R.
  • Singh, Daljit C. N. G.
  • Romer, Catherine
  • Rao, Abhishek B.
  • Brammer, Lee
  • Adams, Harry
  • Wright, James
  • Boerjan, W.
  • Luterbacher, Jeremy
  • Mansfield, S. D.
  • Motagamwala, Ali Hussain
  • Dumesic, James
  • Shuai, Li
  • Gonzales-Vigil, E.
  • Zhou, Shengfei
  • Mottiar, Y.
  • Dixon, Richard
  • Rencoret, Jorge
  • Río Andrade, José Carlos Del
  • Vanholme, R.
  • Kim, Hoon
  • Lan, Wu
  • Runge, Troy
  • Ralph, John
  • Li, Yanding
  • Karlen, S. D.
  • Chen, Fang
OrganizationsLocationPeople

document

P234 Online direct-to-public calprotectin testing in the UK: what is out there in 2023?

  • Goodhand, J. R.
  • Ahmad, T.
  • Smith, Rebecca
  • Bishara, M.
  • Kennedy, N. A.
  • Roberts, C.
  • Nice, R.
Abstract

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The longest component of the time-to-diagnosis is the interval between symptom onset and an individual seeking help. Recent reports in patients with sexually transmitted infections and hepatitis C, who also suffer health related stigma and a delay in diagnosis, suggest that this barrier may be overcome by the anonymity of direct-to-public testing. We sought to characterise the availability of online direct-to-public calprotectin testing in 2023 in the UK.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We undertook an online search using the Google search engine on May 25th, 2023, with the terms "buy" or "purchase" AND "calprotectin" AND "inflammatory bowel disease". Collection kits were procured, and stool samples tested to receive follow-up advice for known positive and negative stool samples. We recorded data regarding the assay, consumer information and the clinical advice offered on return of a positive and negative test.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Overall, 54.5% (6/11) of available tests were home lateral flow tests, the remainder were home collection laboratory-based tests. Of the laboratory-based tests, three were conventional enzyme-linked immunosorbent assay (ELISA) assays and two were OC sensor tests. The lateral flow tests were considerably cheaper than the laboratory-based tests (median cost £14.20 [£7.85-21.00] vs £75.85 [£59-151], p&amp;lt;0.0001). The median turnaround time for the laboratory tests was 14 (1-23) days. All but one provider used a positivity threshold of 50ug/g. Eight of the eleven platforms (4 lateral flow tests and 4 laboratory-based tests) explicitly stipulated testing in the setting of gastrointestinal symptoms or suggested exclusion criteria. All tests included written and pictorial instructions with the testing kit. The median Flesch Kincaid readability score for the instructions and result reporting were 54.3 (43.9-73.7) and 51.8 (12.9-64.9): equivalent to a school reading grade of 9.2 (6.2-10.8) and 11.3 (7.2-15.8), respectively. Only two of the lateral flow tests provided written recommendations about follow up of positive results, whereas amongst the laboratory-based tests, all but one provider recommended onward discussion with a general practitioner or specialist. Two providers offered private referrals or consultations and six provided safety netting advice with regards to negative results.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In the UK online direct-to-public calprotectin testing is already readily available from multiple providers. Consumers can choose between home-based lateral flow tests or conventional laboratory testing. Further work is needed to redefine the diagnostic accuracy of calprotectin used in this way, however, the rapid turnaround times and anonymity suggest that direct-to-public calprotectin testing could be used to reduce the time to IBD diagnosis.</jats:p></jats:sec>

Topics
  • impedance spectroscopy
  • size-exclusion chromatography